Kathleen A. Elias
YOU?
Author Swipe
View article: Data from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Data from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma Open
Purpose: The RET proto-oncogene has been implicated in breast cancer, and the studies herein describe the preclinical and safety assessment of an anti-RET antibody–drug conjugate (ADC) being developed for the treatment of bre…
View article: Supplementary Methods, Figures 1-3, Table 1 from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Supplementary Methods, Figures 1-3, Table 1 from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma Open
Supplementary Methods, Figures 1-3, Table 1. Supplementary Table S1. Cytotoxicity assessment of maytansine conjugates in RET-positive cell lines (IC50 {plus minus} SE [nM]); Supplementary Figure S1. Breast cancer patient survival was strat…
View article: Data from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Data from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma Open
Purpose: The RET proto-oncogene has been implicated in breast cancer, and the studies herein describe the preclinical and safety assessment of an anti-RET antibody–drug conjugate (ADC) being developed for the treatment of bre…
View article: Supplementary Methods, Figures 1-3, Table 1 from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma
Supplementary Methods, Figures 1-3, Table 1 from Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma Open
Supplementary Methods, Figures 1-3, Table 1. Supplementary Table S1. Cytotoxicity assessment of maytansine conjugates in RET-positive cell lines (IC50 {plus minus} SE [nM]); Supplementary Figure S1. Breast cancer patient survival was strat…